Epidemiology as a Guide to Clinical Decisions: The Association between Triglyceride and Coronary Heart Disease

New England Journal of Medicine

Volumn 302, Issue 25, 1980, Pages 1383-1389

  Hulley, Stephen B ^a,b   Rosenman, Ray H ^a   Bawol, Richard D ^a   Brand, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; DECISION MAKING; EPIDEMIOLOGY; HEALTH CARE POLICY; HUMAN; MEDICAL ETHICS; MIDDLE AGED; RETROSPECTIVE STUDY; RISK;

ADULT; CHOLESTEROL; CORONARY DISEASE; DECISION MAKING; EPIDEMIOLOGIC METHODS; ETHICS, MEDICAL; HEALTH POLICY; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; TRIGLYCERIDES;

EID: 0019328877     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198006193022503     Document Type: Article

References (97)

1. Albrink M.J., Man E.B. Serum triglycerides in coronary artery disease. Arch Intern Med. 1959; 103:4-8.
2. Albrink M.J., Meigs J.W., Man E.B. Serum lipids, hypertension and coronary artery disease. Am J Med. 1961; 31:4-23.
3. Antonis A., Bersohn I. Serum-triglyceride levels in South African Europeans and Bantu and in ischaemic heart disease. Lancet. 1960; 1:998-1002.
4. Carlson L.A. Serum lipids in men with myocardial infarction. Acta Med Scand. 1960; 167:399-413.
5. Schrade W., Boehle E., Biegler R. Humoral changes in arteriosclerosis: investigations on lipids, fatty acids, ketone bodies, pyruvic acid, lactic acid, and glucose in the blood. Lancet. 1960; 2:1409-1416.
6. Nicolaysen R., Westlund K. Plasma lipids in coronary heart disease. Scand J Clin Lab Invest. 1963; 15:291-298.
7. Hayes D., Neill D.W. Serum cholesterol and triglycerides in ischaemic heart disease. Clin Sci. 1964; 26:185-192.
8. Brown D.F., Kinch S.H., Doyle J.T. Serum triglycerides in health and in ischemic heart disease. N Engl J Med. 1965; 273:947-952.
9. Brown D.F. Blood lipids and lipoproteins in atherogenesis. Am J Med. 1969; 46:691-704.
10. Carlson L.A., Wahlberg F. Serum lipids, intravenous glucose tolerance their interrelation studied in ischaemic cardiovascular disease. Acta Med Scand. 1966; 180:307-315.
11. Rosenman R.H., Friedman M., Straus R., Jenkins C.D., Zyzanski S.J., Wurm M. Coronary heart disease in the Western Collaborative Group Study. J Chronic Dis. 1970; 23:173-190.
12. Rosenman R.H., Brand R.J., Sholtz R.I., Friedman M. Multivariate prediction of coronary heart disease during 8.5 year follow-up in the Western Collaborative Group Study. Am J Cardiol. 1976; 37:903-910.
13. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1971; 74:1-12.
14. Kannel W.B., Castelli W.P., Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med. 1979; 90:85-91.
15. Carlson L.A., Böttiger L.E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol: Stockholm prospective study. Lancet. 1972; 1:865-868.
16. Carlson L.A., Böttiger L.E., Åhfeldt P.-E. Risk factors for myocardial infarction in the Stockholm prospective study: a 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand. 1979; 206:351-360.
17. Gustafson A., Elmfeldt D., Wilhelmsen L., Tibblin G. Serum lipids and lipoproteins in men after myocardial infarction compared with representative population sample. Circulation. 1972; 46:709-716.
18. Goldstein J.L., Hazzard W.R., Schrott H.G., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarctions. J Clin Invest. 1973; 52:1533-1543.
19. Wilhelmsen L., Wedel H., Tibblin G. Multivariate analysis of risk factors for coronary heart disease. Circulation. 1973; 48:950-958.
20. Tibblin G., Wilhelmsen L., Werkö L. Risk factors for myocardial infarction and death due to ischemic heart disease and other causes. Am J Cardiol. 1975; 35:514-522.
21. Lewis B., Chait A., Oakley C.M.O., et al. Serum lipoprotein abnormalities in patients with ischaemic heart disease: comparisons with a control population. Br Med J. 1974; 3:489-493.
22. The Coronary Drug Project Research Group. Natural history of myocardial infarction in the Coronary Drug Project: long-term prognostic importance of serum lipid levels. Am J Cardiol. 1978; 42:489-498.
23. Castelli W.P., Doyle J.T., Gordon T., et al. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Pheno-typing Study. Circulation. 1977; 55:767-772.
24. Robertson T.L., Kato H., Gordon T., et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Am J Cardiol. 1977; 39:244-249.
25. Pelkonen R., Nikkilä E.A., Koskinen S., Penttinen K., Sarna S. Association of serum lipids and obesity with cardiovascular mortality. Br Med J. 1977; 2:1185-1187.
26. Wilhelmsen L., Bengtsson C., Elmfeldt D., et al. Multiple risk prediction of myocardial infarction in women as compared with men. Br Heart J. 1977; 39:1179-1185.
27. Brunner D., Altman S., Loebl K., Schwartz S., Levin S. Serum cholesterol and triglycerides in patients suffering from ischemic heart disease and in healthy subjects. Atherosclerosis. 1977; 28:197-204.
28. Cramer K., Paulin S., Werkö L. Coronary angiographic findings in correlation with age, body weight, blood pressure, serum lipids, and smoking habits. Circulation. 1966; 33:888-900.
29. Heinle R.A., Levy R.I., Frederickson D.S., Gorlin R. Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery disease. Am J Cardiol. 1969; 24:178-186.
30. Cohn P.F., Gabbay S.I., Weglicki W.B. Serum lipid levels in angiographically defined coronary artery disease. Ann Intern Med. 1976; 84: 241-5.
31. Gotto A.M., Gorry G.A., Thompson J.R., et al. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation. 1977; 56:875-883.
32. Barboriak J.J., Barboriak D.P., Anderson A.J., et al. Risk factors in patients undergoing a second aorta-coronary bypass procedure. J Thorac Cardiovasc Surg. 1978; 76:111-114.
33. Rhoads G.G., Blackwelder W.C., Stemmermann G.N., Hayashi T., Kagan A. Coronary risk factors and autopsy findings in Japanese-American men. Lab Invest. 1978; 38:304-311.
34. Levy R.I., Fredrickson D.S. Diagnoses and management of hyperlipoproteinemia. Am J Cardiol. 1968; 22:576-583.
35. American Heart Association. Use of diet therapy in hyperlipidemia — a guide for physicians (AHA publication no?. 10-74-10M). New York: American Heart Association, 1974.
36. Ahrens E.H. Jr. The management of hyperlipidemia: whether, rather than how. Ann Intern Med. 1976; 85:87-93.
37. Glueck C.J. Fat: appraisal of dietary fat as a causative factor in atherogenesis. Am J Clin Nutr. 1979; 32:2637-2643.
38. Conference on the health effects of blood lipids: optimal distributions for populations: workshop report: epidemiological section. Prev Med. 1979; 8:612-678.
39. Conference on the health effects of blood lipids: optimal distributions for populations: workshop report: clinical-pathological section. Prev Med. 1979; 8:679-714.
40. Bierman E.L. Atherosclerosis and other forms of arteriosclerosis. In: Isselbacher KJ, Adams RD, Braunwald E, Petersdorf RG, Wilson JD, eds. Harrison#x0027;s principles of internal medicine. 9th edition. New York: McGraw-Hill, 1980: 1156-66.
41. Tzagournis M. Triglycerides in clinical medicine: a review. Am J Clin Nutr. 1978; 31:1437-1452.
42. Glueck C.J., McGill H.C. Jr., Shank R.E., Lauer R.M. Value and safety of diet modification to control hyperlipidemia in childhood and adolescence: a statement for physicians. Circulation. 1978; 58:381A-385A.
43. Moloney T.W., Rogers D.E. Medical technology — a different view of the contentious debate over costs. N Engl J Med. 1979; 301:1413-1419.
44. Relman A.S. Technology costs and evaluation. N Engl J Med. 1979; 301:1444-1445.
45. Evans A.S. Causation and disease: a chronological journey. Am J Epidemiol. 1978; 108:249-258.
46. Stamler J. Lifestyles, major risk factors, proof and public policy. Circulation. 1978; 58:3-19.
47. Hulley S.B. The high density lipoproteins: an epidemiological review. Adv Exp Med Biol. 1978; 109:295-315.
48. Brand R.J., Paffenbarger R.S. Jr., Sholtz R.I., Kampert J.B. Work activity and fatal heart attack studied by multiple logistic risk analysis. Am J Epidemiol. 1979; 110:52-62.
49. Cornfield J. Principles of research. Am J Ment Defic. 1959; 64:240-252.
50. Tibblin G., Cramér K. Serum lipids during the course of an acute myocardial infarction and one year afterwards. Acta Med Scand. 1963; 174:451-455.
51. Dodds C., Mills G.L. Influence of myocardial infarction on plasmalipoprotein concentration. Lancet. 1959; 1:1160-1163.
52. Rosenman R.H., Friedman M., Straus R., et al. A predictive study of coronary heart disease: the Western Collaborative Group Study. JAMA. 1964; 189:15-22.
53. Rosenman R.H., Brand R.J., Scholtz R.I., Jenkins C.D. Relation of corneal arcus to cardiovascular risk factors and the incidence of coronary disease. N Engl J Med. 1974; 291:1322-1324.
54. Rosenman R.H., Brand R.J., Jenkins C.D., Friedman M., Straus R., Wurm M. Coronary heart disease in the Western Collaborative Group Study. JAMA. 1975; 233:872-877.
55. Fredrickson D.S., Levy R.I., Lees R.S. Fat transport in lipoproteins — an integrated approach to mechanisms and disorders. N Engl J Med. 1967; 276:34-44, 94-103, 148-56, 215-25, 273-81.
56. Grundy S.M. Cholesterol metabolism in man. West J Med. 1978; 128:13-25.
57. Steinberg D. Research related to underlying mechanisms in atherosclerosis. Circulation. 1979; 60:1559-1565.
58. Strisower E.H., Adamson G., Strisower B. Treatment of hyperlipidemias. Am J Med. 1968; 45:488-501.
59. Carlson L.A., Olsson A.G., Orö L., Rössner S., Walldius G. Effects of hypolipidemic regimes on serum lipoproteins. In: Schettler G, Weizel A, eds. Atherosclerosis III. New York: Springer-Verlag, 1974: 768-81.
60. Kuller L., Caggiula A., Smith W.M., et al. Determinants of plasma triglycerides and VLDL cholesterol in the MRFIT study. Presented at a meeting of the American Oil Chemistry Society, San Francisco, May 3, 1979.
61. Connor W.E., Connor S.L. Dietary treatment of hyperlipidemia. In: Rifkind BM, Levy RI, eds. Hyperlipidemia: diagnosis and therapy. New York: Grune & Stratton, 1977: 281-326.
62. McGandy R.B., Hegsted D.M., Stare F.J. Dietary fats, carbohydrates and atherosclerotic vascular disease. N Engl J Med. 1967; 277:186-92, 242-7.
63. Wilson W.S., Hulley S.B., Burrows M.I., Nichaman M.Z. Serial lipid and lipoprotein responses to the American Heart Association fat-controlled diet. Am J Med. 1971; 51:491-503.
64. Nestel P.J., Carroll K.F., Havenstein N. Plasma triglyceride response to carbohydrates, fats and calorie intake. Metabolism. 1970; 19:1-18.
65. Herbert P.N., Henderson L.O. Plasma-triglycerides do not regulate high-density lipoprotein concentrations. Lancet. 1979; 1:1368-1370.
66. Reisin E., Abel R., Modan M., Silverberg D.S., Eliahou H.E., Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978; 298:1-6.
67. Hulley S.B., Ashman P., Kuller L., Lasser N., Sherwin R. HDL-cholesterol levels in the Multiple Risk Factor Intervention Trial (MRFIT). Lipids. 1979; 14:119-125.
68. Ahrens A.H. Jr. Introduction to symposium report on dietary factors relating to the nation#x0027;s health. Am J Clin Nutr. 1979; 32:2627-2631.
69. Stern M.P. The recent decline in ischemic heart disease mortality. Ann Intern Med. 1979; 91:630-640.
70. Stamler J. Research related to risk factors. Circulation. 1979; 60:1575-1587.
71. Böttcher C.J.F., Boelsma-van Houte E., Romeny-Wachter C.C., Woodford F.P., van Gent C.M. Lipid and fatty-acid composition of coronary and cerebral arteries at different stages of atherosclerosis. Lancet. 1960; 2:1162-1166.
72. McGill H.C. Atherosclerosis: problems in pathogenesis. In: Paoletti R, Gotto AM, eds. Atherosclerosis Reviews. Vol. 2. New York: Raven Press, 1977; 2:27-65.
73. Small D.M. Cellular mechanisms for lipid deposition in atherosclerosis. N Engl J Med. 1977; 297:873-877.
74. Borhani N.O. Primary prevention of coronary heart disease: a critique. Am J Cardiol. 1977; 40:251-259.
75. Davis C.E., Havlik R.J. Clinical trials of lipid lowering and coronary artery disease prevention. In: Rifkind BM, Levy RI, eds. Hyperlipidemia: diagnosis and therapy. New York: Grune & Stratton, 1977: 79-92.
76. Sherwin R. Controlled trials of the Diet-Heart Hypothesis: some comments on the experimental unit. Am J Epidemiol. 1978; 108:92-99.
77. Oliver M.F. Cholesterol, coronaries, clofibrate and death. N Engl J Med. 1978; 299:1360-1362.
78. McGill H.C. Jr. The relationship of dietary cholesterol to serum cholesterol concentration and to atherosclerosis in man. Am J Clin Nutr. 1979; 32:2664-2702.
79. Mann G.V. Diet-heart: end of an era. N Engl J Med. 1977; 297:644-650.
80. Vil C.S., Kohn K.H., Last J., et al. Diet-heart era: premature obituary? N Engl J Med. 1978; 298:109-110.
81. Glueck C.J., Mattson F., Bierman E.L. Diet and coronary heart disease: another view. N Engl J Med. 1978; 298:1471-1474.
82. Glueck C.J., Connor W.E. Diet-coronary heart disease relationships reconnoitered. Am J Clin Nutr. 1978; 31:727-737.
83. McMichael J. Fats and atheroma: an inquest. Br Med J. 1979; 1: 173-5.
84. Stamler J. Public health aspects of optimal serum lipid-lipoprotein levels. Prev Med. 1979; 8:733-759.
85. Ahrens E.H. Dietary fats and coronary heart disease: unfinished business. Lancet. 1979; 2:1345-1348.
86. Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231:360-381.
87. Oliver M.F., Heady J.A., Morris J.N., et al. A Cooperative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J. 1978; 40:1069-1119.
88. McKeown T. Unvalidated procedures have no place in screening programs. In: Ingelfinger FJ, Ebert RV, Finland M, Relman AS, eds. Controversies in internal medicine II. Philadelphia: WB Saunders, 1974: 92-8.
89. Spitzer W.O., Brown B.P. Unanswered questions about the periodic health examination. Ann Intern Med. 1975; 83:257-263.
90. Jonsen A.R. Do no harm. Ann Intern Med. 1978; 88:827-832.
91. The Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA. 1972; 220:996-1008.
92. The Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA. 1973; 226:652-7
93. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970; 19: Suppl 2:785-830.
94. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes. 1975; 24: Suppl 1:65-184.
95. Ederer F., Leren P., Turpeinen O., Frantz I.D. Jr. Cancer among men on cholesterol-lowering diets: experience from five clinical trials. Lancet. 1971; 2:203-206.
96. Lees R.S. Clofibrate and atherosclerosis. N Engl J Med. 1979; 300:491-492.
97. Haynes R.B., Sackett D.L., Taylor D.W., Gibson E.S., Johnson A.L. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med. 1978; 299:741-744.